Savill Corrine
SEC CIK 1837524 · EDGAR
BoughtSold
Companies
| Ticker | Company | Title | Holding | Bought | Sold | Trades | First | Last |
|---|---|---|---|---|---|---|---|---|
| CGEM | Cullinan Therapeutics, Inc. | Chief Business Off | 241.0K | — | $2.54M | 12 | 2022-02-11 | 2025-02-19 |
Most active insiders at CGEM, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | Lynx1 Capital Management LP | 10% | $11.93M | — |
| 2 | Michaelson Jennifer | CSO | — | $1.62M |
| 3 | Nichols Weston | 10% | $1.39M | — |
| 4 | AHMED NADIM | Pres, CEO, Dir | — | $518.0K |
| 5 | Jones Jeffrey Alan | Chief Medical Off | — | $178.9K |
| 6 | SUMER JACQUELYN L | CLO | — | $136.7K |
| 7 | Fenton Mary Kay | CFO | — | $59.9K |
Savill Corrine made no open-market trades at CGEM in the last 12 months.
Transactions 12
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-02-21 | 2025-02-19 | CGEM | Cullinan Therapeutics, Inc. | Savill Corrine | Chief Business Off | A - Grant | $0.00 | +37.5K | 241.0K | +18% | $0 |
| D | 2024-02-23 | 2024-02-22 | CGEM | Cullinan Therapeutics, Inc. | Savill Corrine | Chief Business Off | A - Grant | $0.00 | +37.5K | 203.5K | +23% | $0 |
| DT | 2024-02-02 | 2024-02-01 | CGEM | Cullinan Therapeutics, Inc. | Savill Corrine | Chief Business Off | S - Sale+OE | $16.18 | -40.0K | 166.0K | -19% | -$647.2K |
| DT | 2024-02-02 | 2024-02-01 | CGEM | Cullinan Therapeutics, Inc. | Savill Corrine | Chief Business Off | M - OptEx | $4.30 | +40.0K | 206.0K | +24% | +$172.0K |
| DT | 2024-01-30 | 2024-01-29 | CGEM | Cullinan Therapeutics, Inc. | Savill Corrine | Chief Business Off | M - OptEx | $4.30 | +40.0K | 206.0K | +24% | +$172.0K |
| DT | 2024-01-30 | 2024-01-29 | CGEM | Cullinan Therapeutics, Inc. | Savill Corrine | Chief Business Off | S - Sale+OE | $14.09 | -40.0K | 166.0K | -19% | -$563.6K |
| DMT | 2024-01-24 | 2024-01-22+ | CGEM | Cullinan Therapeutics, Inc. | Savill Corrine | Chief Business Off | M - OptEx | $4.30 | +35.9K | 187.3K | +24% | +$154.3K |
| DMT | 2024-01-24 | 2024-01-22+ | CGEM | Cullinan Therapeutics, Inc. | Savill Corrine | Chief Business Off | S - Sale+OE | $12.31 | -40.0K | 166.0K | -19% | -$492.5K |
| D | 2023-02-21 | 2023-02-17 | CGEM | Cullinan Therapeutics, Inc. | Savill Corrine | Chief Business Off | A - Grant | $0.00 | +20.5K | 170.1K | +14% | $0 |
| M | 2022-07-21 | 2022-07-18+ | CGEM | Cullinan Therapeutics, Inc. | Savill Corrine | Acting Chief Business Off | S - Sale | $15.18 | -20.0K | 149.6K | -12% | -$303.6K |
| M | 2022-07-12 | 2022-07-11 | CGEM | Cullinan Therapeutics, Inc. | Savill Corrine | Acting Chief Business Off | S - Sale | $13.33 | -40.0K | 169.8K | -19% | -$533.3K |
| D | 2022-02-15 | 2022-02-11 | CGEM | Cullinan Therapeutics, Inc. | Savill Corrine | Acting Chief Business Off | A - Grant | $0.00 | +16.5K | 209.6K | +9% | $0 |
Purchase Sale Sale after option exercise All abbreviations